Enrollment has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec for the treatment of severe and moderately severe hemophilia B.-uniQure N.V.

uniQure N.V.has announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec (AMT-061), an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. Due to the high level of interest in the study from both patients and study investigators, uniQure expects to over-enroll up to six additional patients before the end of September.

Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the FDA and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency.

The pivotal Phase III HOPE-B study builds on the success of the interim 36-week results of the Company�s ongoing Phase IIb study of etranacogene dezaparvovec, which demonstrated that a single administration of the investigational gene therapy resulted in sustained increases in Factor IX (FIX) levels up to 54% of normal, and a mean FIX level of 45% of normal. During that time, no patient reported any bleeding events or required any infusion of FIX replacement therapy for bleeds or experienced any material loss of FIX activity. Additionally, an ongoing Phase I/II study of AMT-060, the Company�s first-generation gene therapy for the treatment of hemophilia B, demonstrated that all 10 patients continue to show sustained and stable increases in FIX activity and long-term clinical benefits at up to 3.5 years of observation.